The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Open accessPublished version of a preprint
Abstract
Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial–mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC. Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404–15. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 1317
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Rociletinib (CO-1686; Clovis Oncology) is a small-molecule, orally available, mutant-selective covalent inhibitor of commonly mutated forms of EGFR, including exon 19 deletions, L858R, and T790M, but not exon 20 insertions.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (XegafriTM, CO-1686) (65), developed by Clovis Oncology, is a specific mutant agent for the treatment of NSCLC, belonging to the third-generation EGFR TKIs.190,191”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [190]
In the citing paper
“Additionally, covalent inhibitors can exhibit high selectivity for proteins with non-conserved residues between variant forms or protein family members [41].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [41]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Indeed, pre-clinical reports have suggested that “third generation” agents can induce switching to multiple signaling mechanisms that bypass EGFR dependency such as ERK and AKT pathways (35, 61, 62).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Preclinical studies have confirmed that rociletinib has minimal activity against wild-type EGFR.7”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“In xenograft models with EGFR-activating mutations alone or combined with T790M resistance mutations, rociletinib resulted in durable tumor shrinkage, 7 which was most marked when plasma concentrations were maintained at more than 200 ng per milliliter across the dosing interval.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Indeed, it seems that EGFR monoclonal antibodies 60 and EGFR WT kinase sparing covalent T790M selective TKIs 61 are ineffective in typical EGFR exon 20 insertion mutants.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [61]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“Additional pre-clinical studies have also identified activation of MAPK signaling and IGF1R signaling as well as epithelial to mesenchymal (EMT) transition as potential resistance mechanisms to WZ4002 and CO-1686 (15, 19, 20).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“In vitro and in vivo studies demonstrated that Rociletinib irreversibly and selectively inhibits mutant EGFR, including T790M mutation, with minimal activity against wild type EGFR, suggesting that drug tolerability to this agent may be superior to first and second generation EGFR inhibitors”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [85]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“Osimertinib and rociletinib are 3rd generation EGFR-TKIs, both of which are reported to be effective in lung cancer cells harboring EGFR T790M in preclinical models [30, 32].”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“Patients with the most common EGFR mutations (L858R mutation in exon 21 and delE746-A750 deletions in exon 19) typically have good responses to therapy with first-generation reversible EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib (3-5).”
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“second site EGFR point mutation that results in the substitution of threonine with methionine at amino acid position 790 (T790M;(7-10)).”
BackgroundSelf-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citation
Cited by
Sorted by citations
Items 401–500 of 686
Xu, J., Zhao, X., He, D., Wang, J., Li, W., Liu, Y., Ma, L., Jiang, M., Yu, T., Wang, Z., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2668-7 · Cited by 16
Self-citationKu, B. M., Bae, Y.-H., Koh, J., Sun, J., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0350-y · Cited by 16
Self-citationStrategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16
Wieczorek, S., Breitenbuecher, F., Soni, A., Paul‐Konietzko, K., Ziegler, S., Sak, A., Iliakis, G. E., & Schüler, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2427-1 · Cited by 16
Biswas, B., Ghadyalpatil, N. S., Krishna, M. V., & Deshmukh, J. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_589_17 · Cited by 16
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies
Attili, I., Re, M. D., Guerini‐Rocco, E., Crucitta, S., Pisapia, P., Pepe, F., Barberis, M. C. P., Troncone, G., Danesi, R., de Marinis, F., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1943365 · Cited by 17
Rational design of non-resistant targeted cancer therapies
Martínez-Jiménez, F., Overington, J. P., Al‐Lazikani, B., & Martı́-Renom, M. A. (2017) · Scientific Reports · doi:10.1038/srep46632 · Cited by 17
Qi, Y., Chen, Y., Tang, B., Xiao, Q., Qu, R., Tong, L., Liu, J., Ding, J., Chen, Y., Ding, N., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.052 · Cited by 16
Suriya, U., Mahalapbutr, P., Wimonsong, W., Yotphan, S., Choowongkomon, K., & Rungrotmongkol, T. (2022) · Molecules · doi:10.3390/molecules27248901 · Cited by 15
Todsaporn, D., Zubenko, A. A., Kartsev, V. G., Mahalapbutr, P., Geronikaki, A. A., Sirakanyan, S. N., Диваева, Л. Н., Chekrisheva, V., Yıldız, İ., Choowongkomon, K., et al. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c06246 · Cited by 15
Chen, Y., Deng, J., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-2925 · Cited by 15
Pal, D., Tepeš, P. Š., Lindsted, T., Ibarra, I., Lujambio, A., Sabinina, V. J., Şentürk, Ş., Miller, M. A., Korimerla, N., Huang, J., et al. (2021) · eLife · doi:10.7554/elife.66109 · Cited by 15
Erbay, T. G., Dempe, D. P., Godugu, B., Liu, P., & Brummond, K. M. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c01335 · Cited by 15
Surapaneni, S. K., Nottingham, E., Mondal, A., Patel, N., Arthur, P., Gebeyehu, A., Kalvala, A. K., Rishi, A. K., & Singh, M. S. (2021) · Anticancer Research · doi:10.21873/anticanres.15226 · Cited by 15
Capicua Suppresses YAP1 To Limit Tumorigenesis and Maintain Drug Sensitivity in Human Cancer
Kim, J. W., Luck, C., Wu, W., Ponce, R. K., Lin, Y. K., Gupta, N., & Okimoto, R. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2022.111443 · Cited by 15
Bencze, E., Bogos, K., Kohánka, A., Báthory-Fülöp, L., Sárosi, V., Csernák, E., Bittner, N., Melegh, Z., & Tóth, E. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610607 · Cited by 15
Wang, Y., Guo, Z., Yang, L., & Zhou, Q. (2016) · Open Medicine · doi:10.1515/med-2016-0014 · Cited by 16
Song, A., Zhang, J., Yang, G., Wang, C., Meng, Q., Tang, Z., Peng, J., Liu, K., Li, Y., & Ma, X. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.032 · Cited by 15
Hu, J., Han, Y., Wang, J., Liu, Y., Zhao, Y., Liu, Y., & Gong, P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.029 · Cited by 16
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC
Chen, L., Chi, F., Wang, T., Wang, N., Li, W., Liu, K., Shu, X. H., Ma, X., & Xu, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.009 · Cited by 15
Changing Histopathological Diagnostics by Genome-Based Tumor Classification
Kloth, M. T., & Buettner, R. (2014) · Genes · doi:10.3390/genes5020444 · Cited by 15
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Wu, W.-S., & Chen, Y. (2014) · Journal of Personalized Medicine · doi:10.3390/jpm4030297 · Cited by 14
New strategies to develop new medications for lung cancer and metastasis
Zhao, Y., & Adjei, A. A. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9553-5 · Cited by 14
The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance
Davidsen, K. T., Haaland, G. S., Lie, M. K., Lorens, J. B., & Engelsen, A. S. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_15 · Cited by 14
Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice
Chung, C.-T., Yeh, K., Lee, C., Chen, Y., Ho, P.-J., Chang, K.-Y., Chen, C., Lai, Y., & Chen, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105183 · Cited by 14
Park, H., Jung, H.-Y., Kim, K., Kim, M., & Hong, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239323 · Cited by 14
Pei, J., Wang, G., Wang, A., Wu, C., Pan, X., Wen, S., Bu, F., Zhu, Y., Wang, Y., Ouyang, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00027 · Cited by 15
Downregulation of AP1S1 causes the lysosomal degradation of EGFR in non‐small cell lung cancer
Jeong, J., Hwang, Y. E., Lee, M., Keum, S., Song, S., Kim, J., Choi, J., & Rhee, S. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31112 · Cited by 14
Ochi, N., Isozaki, H., Takeyama, M., Singer, J. W., Yamane, H., Honda, Y., Kiura, K., & Takigawa, N. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.05.008 · Cited by 14
Huang, J., Huang, J., Wang, N., Wang, L., Li, L., Wang, C., Sun, X., Li, Y., Huang, G., & Ma, X. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102994 · Cited by 14
Hao, Y., Lyu, J., Qu, R., Sun, D., Zhao, Z., Chen, Z., Ding, J., Xie, H., Xu, Y. F., & Li, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04184-9 · Cited by 14
Wu, C., Zhong, R., Wei, T., Jin, Y., He, C., Li, H., & Cheng, Y. (2024) · Oncology Letters · doi:10.3892/ol.2024.14431 · Cited by 13
Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications
Pimentel, L. C. F., Cunha, A. C., Hoelz, L. V. B., Canzian, H. F., Leite, D. I., Boechat, N., & Bastos, M. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200124094949 · Cited by 13
Fukuda, T., Anzai, M., Nakahara, A., Yamashita, K., Matsukura, K., Ishibashi, F., Oku, Y., Nishiya, N., Uehara, Y., & Iwao, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116039 · Cited by 13
Wang, H., Wang, X., Xu, L., Lin, Y., & Zhang, J. (2022) · Disease Markers · doi:10.1155/2022/1560199 · Cited by 13
Wang, C.-Y., Sun, Y., Zhu, X., Wu, B., Wang, Q., Zhen, Y., Shu, X. H., Liu, K., Zhou, Y., & Ma, X. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12692 · Cited by 13
Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00010-7 · Cited by 14
Targeting EGFR and ALK in NSCLC: Current Evidence and Future Perspective
Bennati, C., Paglialunga, L., Ricciuti, B., Metro, G., Marcomigni, L., Gili, A., & Crinò, L. (2016) · Lung Cancer Management · doi:10.2217/lmt-2016-0005 · Cited by 14
Aqueous Electrochemical Synthesis of 5-Trifluoromethyluracil in Batch and Continuous Flow
Gong, R., Zhou, Y., Sui, D., Chen, Y., & Chen, W. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00361 · Cited by 12
González-Larriba, J. L., Lázaro-Quintela, M., Cobo, M., Dómine, M., Majem, M., & García‐Campelo, R. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.03 · Cited by 12
Pan, Y., Lin, C., Lu, C., Li, L., Wang, Y., Chen, H., & He, Y. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12970 · Cited by 12
Nimma, R., Kalvala, A. K., Patel, N., Surapaneni, S. K., Sun, L. J., Singh, R. K., Nottingham, E., Bagde, A., Kommineni, N., Arthur, P., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061156 · Cited by 12
To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Basu, D., Pal, R., Sarkar, M., Barma, S., Halder, S., Roy, H., Nandi, S., & Samadder, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266261150231110053650 · Cited by 12
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, E. H., & Horn, L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0365-1 · Cited by 12
Ito, K., Nishio, M., Kato, M., Murakami, H., Aoyagi, Y., Ohe, Y., Okayama, T., Hashimoto, A., Ohsawa, H., Tanaka, G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0645 · Cited by 12
Fu, J., Yu, J., Zhang, X., Chang, Y., Fan, H., Dong, M., Li, M., Liu, Y., & Hu, J. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2205605 · Cited by 11
SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis
Huang, F., Cui, J., Wan, J., Yuan, X., Zhu, Y., Wu, X., Zuo, W., & Zhao, T. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05416-4 · Cited by 11
Yang, C., Tsai, M., Hung, J., Tsai, Y., Lee, J., Chou, S., Liu, T., Shen, M., Huang, M., & Chong, I. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100169 · Cited by 11
Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer
Lin, Z., Deng, Q., Fang, Q., Li, X., Liu, X., Wang, J., Chen, S., Huang, X., Yang, L., Miao, Y., et al. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2032093 · Cited by 11
Zhang, H., Zhan, C., Ke, J., Xue, Z., Zhang, A., Xu, K., Shen, Z., Yu, L., & Chen, L. (2015) · Oncotarget · doi:10.18632/oncotarget.6491 · Cited by 11
Emerging non‑invasive detection methodologies for lung cancer (Review)
Li, Z., Shu, J., Yang, B., Zhang, Z., Huang, J., & Chen, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.11460 · Cited by 11
Mao, L., Tang, W., Zhang, X., Liu, J., Chen, Y., Hua, Y., Weng, B., Mo, X., Bao, Y., Li, T., et al. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100035 · Cited by 11
Kim, T. Y., Ji, E. S., Lee, J. Y., Kim, J. Y., Yoo, J. S., Szász, A. M., Döme, B., Marko‐Varga, G., & Kwon, H. J. (2020) · Cancers · doi:10.3390/cancers12092613 · Cited by 11
Hennessy, E. J., Chuaqui, C. E., Ashton, S. E., Colclough, N., Cross, D. A. E., Debreczeni, J. E., Eberlein, C., Gingipalli, L., Klinowska, T. C. M., Orme, J. P., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00058 · Cited by 11
Akher, F. B., Farrokhzadeh, A., Ravenscroft, N., & Kuttel, M. M. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c03440 · Cited by 11
Dwivedi, D., Agrawal, R. K., Jain, S., & Kuche, K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230505123802 · Cited by 10
Wang, Q., Zhu, Y., & Pei, J. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2389764 · Cited by 10
Kazaz, S. N., & Öztop, İ. (2017) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2017.16042 · Cited by 10
From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer
Formisano, L., Jansen, V. M., Marciano, R., & Bianco, R. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520617666170912123416 · Cited by 10
Identification of new potential candidates to inhibit EGF via machine learning algorithm
Torabi, M., Yasami‐Khiabani, S., Sardari, S., Golkar, M., Pérez‐Sánchez, H., & Ghasemi, F. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176176 · Cited by 11
Wei, Y., Poon, D. C., Fei, R., Lam, A. S. M., Au‐Yeung, S. C. F., & To, K. K. W. (2016) · Scientific Reports · doi:10.1038/srep25363 · Cited by 10
QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
Fatima, S., Pal, D., & Agarwal, S. M. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13505 · Cited by 10
Han, Y., Kim, S., Park, T.-H., Hwang, H., Park, S., Kim, J. M., Pyun, J., & Lee, M. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01583-24 · Cited by 9
Covalent aptamers: agents with promising therapeutic and diagnostic potential
Albright, S., Boette, J., Cacace, M., & Deiters, A. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00133a · Cited by 9
Direkte Modulation von Aktivität und Funktion kleiner GTPasen
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie · doi:10.1002/ange.201504357 · Cited by 9
Remón, J., & Besse, B. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000081 · Cited by 9
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 10
Burotto, M., Ali, S. A., & Coyne, G. O. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.973400 · Cited by 9
Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure
Choi, J. R., Koh, S. B., Park, S. Y., Kim, H. R., Lee, H., & Kang, D. R. (2017) · Journal of Cancer Prevention · doi:10.15430/jcp.2017.22.4.234 · Cited by 9
Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung
Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201707875 · Cited by 9
Ibrahim, M. T., Uzairu, A., Shallangwa, G. A., & Uba, S. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00107-y · Cited by 9
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac124.52175233 · Cited by 9
Zhou, F., Zhang, L., Jin, Y.-Z., Liu, W., Cheng, P., He, X., Xie, J., Shen, S., Jing, L., Ji, H., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.009 · Cited by 9
Curious effects of fluorine on medicinally active compounds
Honda, T., & Ojima, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819874-2.00008-4 · Cited by 9
Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation
Jin, X., Yang, Y., Liu, D., Zhou, X., & Huang, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01919-w · Cited by 8
Ding, K., Li, Y., Zhou, Y., & Huang, W. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00496 · Cited by 8
Makimoto, G., Ninomiya, K., Kubo, T., Sunami, R., Kato, Y., Ichihara, E., Ohashi, K., Rai, K., Hotta, K., Tabata, M., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab048 · Cited by 8
Self-citationZaitouni, S. E., Laraqui, A., Ghaouti, M., Benzekri, A., Kettani, F., Boustany, Y., Benmokhtar, S., Alaoui, H. L., Annaz, H. E., Abi, R., et al. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241288907 · Cited by 7
Li, L., Li, Y., Ma, X., Li, P., Zeng, S., Jiang, F., & Zhang, G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108864 · Cited by 7
An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR‐Addicted Lung Tumorigenesis
Mokhtari, R. B., Sampath, D., Eversole, P., Lin, M. O. Y., Bosykh, D. A., Boopathy, G. T. K., Sivakumar, A., Wang, C., Kumar, R., Sheng, J. Y. P., et al. (2025) · Advanced Science · doi:10.1002/advs.202413443 · Cited by 8
The steady progress of targeted therapies, promising advances for lung cancer
Bombardelli, L., & Berns, A. J. M. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.638 · Cited by 8
Wang, L., Ding, X., Wang, K., Sun, R., Li, M., Wang, F., & Xu, Y. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134499 · Cited by 7
Small Molecule Inhibitors of the Epidermal Growth Factor Receptor
Finlay, M. R. V., & Ward, R. A. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_26 · Cited by 7
Akher, F. B., Farrokhzadeh, A., & Soliman, M. E. S. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13467 · Cited by 7
Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
Nishimura, Y., & Itoh, K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.15 · Cited by 7
Yi, Y., Wang, L., Zhao, D. Y., Huang, S., Wang, C., Liu, Z., Sun, H., Liu, K., Ma, X., & Li, Y. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13370 · Cited by 7
Sattayawat, P., Kaewkod, T., Thongyim, S., Chiawpanit, C., Wutti‐in, Y., Thepmalee, C., Tragoolpua, Y., Disayathanoowat, T., & Panya, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062498 · Cited by 6
Li, L., Lu, M., Wang, H., Ma, X., Du, W., Zhao, Y., Zeng, S., Peng, Y., & Zhang, G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108393 · Cited by 6
Kumar, V., Chauhan, L., Singh, D., Kumar, A., Kulandaisamy, R., Kushwaha, T., Baswal, K., Singh, R., Kumar, S., Gholap, S. L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570108 · Cited by 6
Yeo, C. D., Kim, I. K., Ban, W. H., Kang, H. S., Kim, J. W., Kim, S. J., Park, J. Y., & Lee, S. H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.05.02 · Cited by 6
Sonker, P., Singh, M., Nidhar, M., Sharma, V. P., Yadav, P., Singh, R., Koch, B., & Tewari, A. K. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0199 · Cited by 6
Bahi, S. E., Boutalaka, M., Alaqarbeh, M., Alaouy, M. A. E., Koubi, Y., Khatabi, K. E., Choukrad, M., Sbai, A., Bouachrıne, M., & Lakhlifi, T. (2023) · Chemistry Africa · doi:10.1007/s42250-023-00744-x · Cited by 7
Drugs That Modulate Resistance to Antitumor Agents
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00014-4 · Cited by 6
Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain
Mozumdar, D., Doerner, A. E., Zhang, J. Y., Rafizadeh, D. N., & Schepartz, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00641 · Cited by 6
Han, C., Ren, J., Su, F., Hu, X., Li, M., Wang, Z., & Wu, L. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200302113206 · Cited by 6
Self-citationAbsence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues
Oscorbin, I. P., Shadrina, A. S., Kozlov, V. V., Voitsitsky, V. E., & Филипенко, М. Л. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00683-4 · Cited by 5
Akher, F. B., Farrokhzadeh, A., Ravenscroft, N., & Kuttel, M. M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01399 · Cited by 5
Generation of genetically engineered mice for lung cancer with mutant EGFR
Kim, D., Ji, W., Kim, D. H., Choi, Y. J., Im, K., Lee, C. W., Cho, J., Min, J., Woo, D., Choi, C., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.104 · Cited by 5
Jiang, J., Wang, C., Yu, X., Sheng, D., Chen, Z., Ren, M., Wu, Y., Shen, J., Jin, M., & Xu, S. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.10.002 · Cited by 5
Metadata
- Authors
- Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, P., Niu, D., Nacht, M., Petter, R. C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., Van Dyke, T., Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A. D., Harding, T. C., & Allen, A.
- Affiliations
- Vanderbilt University (US)
- Authors' Affiliations: 1Clovis Oncology Inc., San Francisco, California; 2Celgene Avilomics Research, Bedford, Massachusetts; 3Division of Hematology-Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; 4Mouse Cancer Genetics Program; and 5Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, Maryland
- Corresponding author
- Harding, Thomas C.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1404-1415
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4048995
- OpenAlex
- W2146418087
- Cited by
- 620
- References
- 43
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 21 · 2023: 29 · 2022: 32 · 2021: 41 · 2020: 51 · 2019: 44 · 2018: 61 · 2017: 87 · 2016: 92 · 2015: 86 · 2014: 44 · 2013: 3
- FWCI
- 62.72
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HHSN261200800001C)
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, HHSN261200800001E), U54CA143798, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- EGFR tyrosine kinase inhibitors, T790M mutation, acquired drug resistance, non-small cell lung cancer, irreversible kinase inhibitors, epithelial-mesenchymal transition, AKT inhibitors, on-target toxicity
- MeSH terms
- Acrylamides, Administration, Oral, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Screening Assays, Antitumor, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mice, Transgenic, Pyrimidines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mutant Proteins, Mice, HEK293 Cells, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
